Expression and clinical significance of long-chain non-coding RNA BCYRN1 in serum of patients with non-small cell lung cancer / 中国医师杂志

ABSTRACT

Objective To investigate the expression and clinical significance of long-chain noncoding RNA brain cytoplasmic RNA 1 (BCYRN1) in serum of patients with non-small cell lung cancer.Methods 74 patients with non-small cell lung cancer (NSCLC) diagnosed and treated in our hospital were selected as the experimental group,and 50 healthy subjects were selected as the control group.The expression of BCYRN1 in serum of NSCLC and control group was detected by real-time quantitative polymerase chain reaction (qRT-PCR).The patients' clinical pathology data were collected and followed up.To analyze the relationship between the expression of serum BCYRN1 and clinicopathological parameters of NSCLC patients,and the relationship between BCYRN1 expression in the diagnosis and prediction of NSCLC prognosis.Results The relative expression of BCYRN1 in serum of NSCLC patients was 2.84 ± 0.95,which was significantly higher than that of healthy controls (1.16 ± 0.50) (P ＜ 0.05).The level of serum BCYRN1 in patients with NSCLC with tumor size ＞ 3 cm was significantly higher than that in patients with tumor size ≤3 cm (P ＜ 0.05).The level of BCYRN1 in patients with tumor node metastasis (TNM) Ⅲ +Ⅳ was significantly higher than that in patients with stage Ⅰ + Ⅱ (P ＜ 0.05).Patients with low differentiation and positive lymph node metastasis had higher serum BCYRN1 than those with moderate to high grade and lymph node metastasis (P ＜ 0.05).The receiver operating characteristic (ROC) curve analysis showed that the area under the curve was 0.847 (95％ CI0.772-0.922,P =0.000),and the sensitivity and specificity were 68.9％ and 88.0％,respectively.The median progression free survival (PFS) (15 vs 21 months) and overall survival (OS) (19 vs 28 months) of patients with high and low expression of BCYRN1 were statistically significant (P ＜ 0.05).High expression of BCYRN1 was an independent risk factor for overall survival in patients with NSCLC.Conclusions BCYRN1 is highly expressed in the serum of NSCLC patients,and high expression of BCYRN1 is closely related to the poor prognosis of patients with NSCLC.It can be used as a novel biomarker and diagnostic target for NSCLC.